Definium Therapeutics, Inc. (DFTX) Discusses Phase III Clinical Progress and Study Outcomes for Lead Program in Mood Disorders Transcript

1 source ·1 article ·Sep 4, 23:59 UTC Definium Therapeutics Information Services

Covered by 1 outlet